# Kilitch Drugs (India) share price today (Kilitch Drugs (India) Ltd, NSE: KILITCH)

> Kilitch Drugs (India) share price today: ₹202.13 at the NSE close on 3 November 2026, up 4.1% in a year. Kilitch Drugs (India) (NSE: KILITCH) is worth ₹708 crore, trades at a P/E of 23.5 and has closed between ₹128.06 and ₹241.61 over the past 52 weeks. > Kilitch Drugs (India) Ltd's P/E is near the low end of its own history, higher than only 16% of past readings, and its quarterly results are still getting worse. KILITCH · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from fewer quarters than usual
- Price: ₹202.13 (+4.1% in a year)
- P/E: 23.5× (lower than 84% of the last 8.1 years)
- Revenue (Jun 2026): ₹44.9 Cr (+4.0% on a year ago)
- Profit (Jun 2026): ₹2.0 Cr (−13.7% on a year ago)
- Operating margin: 6.5% (−1.0 points on a year ago)
- ROCE: 13%, FY26
- Profit that came in as cash: 58%, last 3 years

The main question: the P/E is near the low end of its own history, higher than only 16% of past readings, but results are getting worse. A low multiple can stay low until the quarters turn. ## What is the Kilitch Drugs (India) share price today? Kilitch Drugs (India) Ltd's share price was ₹202.13 at the close on 3 November 2026. It has been rising for 19 weeks. That is 8.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹128 and ₹242, and at that close it sat 65% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 9 weeks in a row. Over the last 11 years the share price moved +932% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Kilitch Drugs (India) this quarter? One change stood out: lowest operating margin in 8 quarters. 1. Lowest operating margin in 8 quarters Operating margin was 6.6% in the June 2026 quarter, against 7.6% a year earlier. ## What are Kilitch Drugs (India)'s latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Kilitch Drugs (India) reported revenue of ₹44.9 crore, up 4.0% from ₹43.1 crore a year earlier, and a profit of ₹1.96 crore, down 13.7% from ₹2.27 crore. ### Kilitch Drugs (India) results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹44.9 crore | ₹43.1 crore | +4.0% |
| Profit | ₹1.96 crore | ₹2.27 crore | −13.7% |
| Earnings per share | ₹0.83 | ₹0.87 | −4.6% |
| Operating margin | 6.5% | 7.6% | −1.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 10 June 2024, about January to March 2024; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Kilitch Drugs (India) share price history? Kilitch Drugs (India) closed at ₹202.13 on 3 November 2026, up 4.1% from ₹194.18 a year earlier (31 October 2025) and up 122.3% over five years. Its highest weekly close since March 2016 was ₹241.61 on 9 October 2026. ### Kilitch Drugs (India) share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹202.24 | −0.1% |
| 1 month ago · 1 Oct 2026 | ₹218.51 | −7.5% |
| 6 months ago · 30 Apr 2026 | ₹154.02 | +31.2% |
| 1 year ago · 31 Oct 2025 | ₹194.18 | +4.1% |
| 3 years ago · 3 Nov 2023 | ₹147.67 | +36.9% |
| 5 years ago · 4 Nov 2021 | ₹90.94 | +122.3% |
| 10 years ago · 4 Nov 2016 | ₹21.26 | +850.8% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹19.59 | +931.8% |
| Highest weekly close since March 2016, also the 52-week high · 9 Oct 2026 | ₹241.61 | −16.3% |
| Lowest weekly close since March 2016 · 24 Jun 2016 | ₹15.76 | +1,182.6% |
| 52-week low (weekly close) · 10 Apr 2026 | ₹128.06 | +57.8% |

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Kilitch Drugs (India)? 3 Nov 2026: Kilitch Drugs (India) closed at ₹202.13, down 0.1% on the week and down 7.5% on the month. Results for April to June 2026: Revenue up 4.0% and profit down 13.7% on a year earlier. ### Earlier

- 24 Mar 2026: Bonus issue: 1 new share for every 1 held (ex-date). - 10 Jun 2024: Kilitch Drugs (India) held its results call for January to March 2024. ## What dividend does Kilitch Drugs (India) pay? Kilitch Drugs (India) has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. Not in its latest year. Kilitch Drugs (India) Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 3 of its last 13 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Kilitch Drugs (India) management say on the latest results call? On the call for January to March 2024, held on 10 June 2024, Kilitch Drugs (India)'s management spoke about the quarter; the main points are below. Source: [the call transcript](https://files.tijorifinance.com/insight/india/2690/Conference Call/CC-Mar24.pdf). (From the call for January to March 2024, 10 June 2024. The April to June 2026 results are out since, so this part may be out of date until we update it.)

## Which stock lists is Kilitch Drugs (India) on? Kilitch Drugs (India) is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 719.3864494337374](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Kilitch Drugs (India) profitable? Kilitch Drugs (India) Ltd earned ₹2.0 Cr of net profit in the Jun 2026 quarter, −13.7% on the same quarter a year earlier. Full-year FY26 profit was ₹30.0 Cr. That is 4.4% of the quarter's revenue. The same quarter a year earlier earned ₹2.3 Cr. For the full year, FY26 profit was ₹30.0 Cr (+20.0% on the year before). Why profit moved: revenue changed +4.0% on a year earlier and the margin moved −1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +0.5% and revenue +12.3%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Kilitch Drugs (India) make, and is it growing? Kilitch Drugs (India) Ltd reported ₹44.9 Cr of revenue in the Jun 2026 quarter, +4.0% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown 27.3% a year on average. The last full year, FY26, came in at ₹235 Cr. The last four reported quarters add to ₹237 Cr. FY26 revenue was ₹235 Cr, +18.7% on the year before. Recent pace: the last four quarters grew +12.3% on average, against 27.3% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +14.0%, against +25.2% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +9.3%, against +65.8% a year (rolling over). ## How much of every ₹100 of sales does Kilitch Drugs (India) keep? Kilitch Drugs (India) Ltd's operating margin was 6.5% in the Jun 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between −19.0% and 16.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −1.0 percentage points on the year while gross margin changed +4.5 points. So the drop came mostly from the gross margin, which means input costs and prices charged. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Kilitch Drugs (India)'s profit turning into cash? Over the last 3 years, 58% of Kilitch Drugs (India) Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹24.0 Cr of operating cash against ₹30.0 Cr of profit. After ₹100 Cr of spending on assets, free cash was −₹76.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 58% of profit came in as cash: the cash cycle got 356 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 356 days longer. The next section looks at where the cash is stuck. ## Where does Kilitch Drugs (India)'s cash go? Kilitch Drugs (India) Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −11 days in FY26, up from −367 days in FY21. It spent ₹149 Cr on assets over the last 3 years. Customers take 186 days to pay, and stock sits for 33 days on average. At FY26 sales of ₹235 Cr, each day of that cycle ties up about ₹0.6 Cr, so roughly −₹7.0 Cr is tied up in the business at any time. FY26: customers took 186 days to pay and stock sat for 33 days, about 1.1 months of sales sitting as stock, for a full cycle of −11 days, longer than FY21's −367. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 33 days. Customers pay about 186 days after that. Suppliers are paid at 230 days. Together that makes the −11-day cycle. Spending on assets: ₹149 Cr over the last 3 years, against ₹10.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹140 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Kilitch Drugs (India)'s P/E ratio, and how does it compare with its own history? Kilitch Drugs (India) Ltd's P/E is 23.5×, near the low end of its own history: it has been lower only 16% of the time. Its usual P/E (the middle reading) is 39.6×, over 8.1 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +13.1% while the price moved +4.1%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +17.3% a year; about +36.4% a year came from earnings growth and about −19.1 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 664% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Kilitch Drugs (India) business getting better or worse? Kilitch Drugs (India) Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +84.9% at its peak to +9.3%, but the business is still expanding, with ROCE steady at 13.0%. This is based on 8 quarters of 4 measures, with some gaps. Why it matters: when the lines disagree, each line above matters more than any single label. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Kilitch Drugs (India) earn on its capital? Kilitch Drugs (India) Ltd earned a ROCE of 13% in FY26. That is up from a low of −10% in FY16. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 12.8% net margin and 0.51× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 12.8% net margin × 0.51× asset turnover × 1.64× leverage (assets divided by equity) ≈ 10.7% on equity. The margin does its share; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 664% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Kilitch Drugs (India) have too much debt? Kilitch Drugs (India) Ltd had ₹89.0 Cr of borrowings against ₹280 Cr of equity in FY26, so its debt is 0.32× its equity. Its operating profit is 6 times its interest bill. Over 5 years borrowings went from ₹15.0 Cr to ₹89.0 Cr. Over the last 3 of those years it spent ₹149 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 664% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Kilitch Drugs (India) shareholding pattern? Promoters cut their stake in Kilitch Drugs (India) Ltd by 5.5 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 63.8% of the company. Domestic institutions moved +0.5 points over the same period, to 0.5%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −5.5 points over 8 quarters, to 63.8%; Domestic institutions: +0.5 points over 8 quarters, to 0.5%; Foreign institutions: +0.1 points over 8 quarters, to 0.1%. Why the owners changed: promoters drove it (−5.5 points), with the other side taken by domestic institutions (+0.5 points). They reduced their stake. ## How far is Kilitch Drugs (India) from balance-sheet trouble? For Kilitch Drugs (India) Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Kilitch Drugs (India) rank in its industry? 51.3 out of 100, rank 21 of 44 in Pharma - Formulators, with 78% of the evidence available. Kilitch Drugs (India) Ltd scores 51.3 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 21. Relative strength against the index is 20%, and revenue and profit growth are weak. The four parts add up to the total exactly: 13.9 + 10.4 + 13.6 + 13.4 = 51.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Kilitch Drugs (India) compared with? Kilitch Drugs (India) ranks 21 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 51.3 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. Kilitch Drugs (India) Ltd this page KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.9/35 · Revenue 14% · Profit 9.3% · Operating margin change -1 points · 83% evidence Capital efficiency 10.4/25 · ROCE 13.4% · Operating margin 6.5% · 76% evidence Valuation 13.6/20 · P/E 23.4× · PEG n/a · 50% evidence Relative strength 13.4/20 · Lead over its industry -3.9% · Lead over NIFTY 500 20% · 1 year 3.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.9 + 10.4 + 13.6 + 13.4 = 51.3 · What this means: Relative strength against the index is 20%, and revenue and profit growth are weak. 22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Kilitch Drugs (India) in size? Kilitch Drugs (India) is the 42nd largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Bafna Pharmaceuticals, Bajaj Healthcare, Lincoln Pharmaceuticals and Zim Laboratories. Just below it: Influx Healthtech and Syncom Healthcare. ### Pharma - Formulators companies close in size

1. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) ₹1,060 crore
2. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) ₹1,031 crore
3. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) ₹1,000 crore
4. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ₹731 crore
5. Kilitch Drugs (India) Ltd ₹704 crore
6. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) ₹612 crore
7. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) ₹17 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Shree Rama Multi-Tech Ltd](https://www.sectoralpha.in/stocks/shree-rama-multi-tech-ltd) ₹708 crore · Packaging - Laminates
2. [Zuari Industries Ltd](https://www.sectoralpha.in/stocks/zuari-industries-ltd) ₹705 crore · Sugar
3. Kilitch Drugs (India) Ltd ₹704 crore
4. [B C C Fuba India Ltd](https://www.sectoralpha.in/stocks/b-c-c-fuba-india-ltd) ₹702 crore · Electronics - Others
5. [Emkay Global Financial Services Ltd](https://www.sectoralpha.in/stocks/emkay-global-financial-services-ltd) ₹702 crore · Finance - Capital Markets - Brokers

## What else do people ask about Kilitch Drugs (India)? ### What were Kilitch Drugs (India)'s latest quarterly results? Kilitch Drugs (India) Ltd reported revenue of ₹44.9 Cr and net profit of ₹2.0 Cr for the Jun 2026 quarter. Revenue rose 4.0% and profit fell 13.7% compared with a year earlier. Earnings per share were ₹0.83. The operating margin was 6.5%, 1.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Kilitch Drugs (India)'s market cap? Kilitch Drugs (India) Ltd's market capitalisation is ₹708 Cr at a share price of ₹202.13. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Kilitch Drugs (India) performing? Kilitch Drugs (India) Ltd's share price has been rising for 19 weeks. In its latest quarter, revenue rose 4.0% and profit fell 13.7% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 9 weeks running (as of 3 November 2026). ### Will Kilitch Drugs (India)'s share price go up? This page does not forecast Kilitch Drugs (India) Ltd's share price. What it shows instead: the share price is ₹202.13, and it has been rising for 19 weeks. Its P/E of 23.5× is higher than 16% of its own last 8 years (as of 3 November 2026). ### Who owns Kilitch Drugs (India)? Promoters own 63.8% of Kilitch Drugs (India) Ltd, foreign institutions 0.1%, domestic institutions 0.5% and the public 35.6% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 5.5 percentage points over 8 quarters (as of 3 November 2026). ### Where is Kilitch Drugs (India) in its business cycle? Kilitch Drugs (India) Ltd's FY26 operating margin was 16.0%, against a 13-year range of −19.0% to 16.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 6.5%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Kilitch Drugs (India) story? The main question: the P/E is near the low end of its own history, higher than only 16% of past readings, but results are getting worse. A low multiple can stay low until the quarters turn. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Kilitch Drugs (India) a stock worth studying right now? What the numbers show: Kilitch Drugs (India) Ltd's P/E is near the low end of its own history, higher than only 16% of past readings, and its quarterly results are still getting worse. The main open question: whether results start to improve. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.